Diarrhoea-related morbidity is reduced by zinc supplementation in HIV-1-infected children. The mechanisms of this effect are largely undefined. We provide evidence for role for Tat (transactivating peptide produced by HIV-1) in the pathogenesis of diarrhoea in AIDS patients. In this study we showed that zinc, preventing Tat-induced fluid secretion, directly limits a specific mechanism of HIV-1-related diarrhoea. Our data support a 'zinc approach' in adjunct to specific antiretroviral therapy in HIV-1-infected children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0b013e328011849a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Characteristics of the Env Regions in HIV-1-Infected Subjects in Baoding City, Hebei Province, China.
Curr HIV Res
January 2025
Clinical Laboratory, The People's Hospital of Baoding, Baoding, Hebei, 071000, China.
Article Synopsis
- The study focuses on the envelope glycoprotein (Env) of HIV-1, which is essential for the virus's ability to infect host cells and is a key target for vaccines and therapies.
- Researchers analyzed the genetic characteristics of the Env gene in 145 newly diagnosed HIV-1 patients in Baoding City, successfully sequencing 142 samples and predicting coreceptor usage.
- Results indicated that 50% of the patients were infected with CCR5-tropic viruses, and specific subtypes showed trends in coreceptor preferences and similarities in the V3 loop's net charges, enhancing insights for vaccine and treatment development.
Association of prior tuberculosis with cardiovascular status in perinatally HIV-1-infected adolescents.
Open Heart
November 2024
Department of Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.
Article Synopsis
- The study investigates how co-occurring HIV and tuberculosis (TB) affect the heart's efficiency in adolescents with HIV acquired at birth (APHIV) in Cape Town, South Africa.
- Researchers hypothesized that APHIV individuals who had previous TB would show worse cardiovascular health due to increased inflammation and disrupted metabolism.
- Results indicated that APHIV with prior TB had lower cardiac efficiency compared to those without TB, but this was not linked to traditional markers of inflammation or lipid levels, suggesting other factors may be involved.
Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis.
EClinicalMedicine
November 2024
School of Public Health, Shenzhen University Medical School, Shenzhen, China.
Background: Despite significant reductions in mother-to-child HIV-1 transmission risks due to the advancements and scale-up of antiretroviral therapy (ART), the global burden of HIV-1 drug resistance (HIVDR) in treatment-naive and treatment-experienced children and adolescents remains poorly understood. In this study, we conducted a systematic review and meta-analysis to estimate the prevalence of HIVDR in these populations globally, regionally, and at the country level.
Methods: We systematically searched PubMed, Embase, and Web of Science for studies reporting HIVDR in treatment-naive and treatment-experienced children and adolescents from inception to June 28, 2024.
HIV-1 envelope glycoproteins (Env) from primary HIV-1 isolates typically adopt a pretriggered "closed" conformation that resists to CD4-induced (CD4i) non-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC). CD4-mimetic compounds (CD4mcs) "open-up" Env allowing binding of CD4i nnAbs, thereby sensitizing HIV-1-infected cells to ADCC. Two families of CD4i nnAbs, the anti-cluster A and anti-coreceptor binding site (CoRBS) Abs, are required to mediate ADCC in combination with the indane CD4mc BNM-III-170.
View Article and Find Full Text PDFDiscovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1.
Bioorg Med Chem Lett
October 2024
State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Sichuan, Chengdu 610041, China. Electronic address:
Article Synopsis
- Viral infectivity factor (Vif) is a promising target for HIV-1 treatments, and researchers have developed a new class of inhibitors that work well against HIV-1 and its drug-resistant strains.
- Using proteolytic targeting chimera (PROTAC), the study explores how to effectively degrade the Vif protein, which is crucial for the virus's ability to replicate.
- The compound L15 has shown a dose-dependent ability to degrade Vif and demonstrated antiviral activity, laying the groundwork for future antiviral drug development using PROTACs for HIV/AIDS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!